-
公开(公告)号:US06933321B2
公开(公告)日:2005-08-23
申请号:US10369267
申请日:2003-02-14
申请人: Fernand Labrie , Shankar Mohan Singh , Van Luu-The
发明人: Fernand Labrie , Shankar Mohan Singh , Van Luu-The
IPC分类号: A61K45/00 , A61K31/085 , A61K31/277 , A61K45/06 , A61P5/28 , A61P13/08 , A61P15/00 , A61P17/00 , A61P17/02 , A61P17/08 , A61P17/10 , A61P17/14 , A61P35/00 , A61P43/00 , C07C255/50 , C07C255/51 , C07C255/54 , C07C255/57 , C07C255/58 , C07D295/192
CPC分类号: C07D295/192 , A61K31/085 , A61K31/277 , C07C255/50 , C07C255/51 , C07C255/54 , C07C255/57 , C07C255/58 , Y02A50/395
摘要: Biphenyl derivatives are disclosed for use in the treatment of androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, precocious puberty, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and premature male baldness. For example, some preferred compounds having the structure: are formulated together with pharmaceutically acceptable diluent or carrier for topical use in the treatment of acne, hirutism, seborrhea or androgenic alopecia, or for systemic use in the treatment of androgen-dependent prostate cancer.
摘要翻译: 公开了联苯衍生物用于治疗雄激素依赖性疾病,例如前列腺癌,良性前列腺增生,早熟性青春期,多囊卵巢综合征,痤疮,多毛症,皮脂溢,雄激素性脱发和过早的男性秃发。 例如,具有以下结构的一些优选化合物与药学上可接受的稀释剂或载体一起配制用于局部用于治疗痤疮,水蛭石,脂溢或雄激素性脱发,或用于全身用于治疗雄激素依赖性前列腺癌。
-
公开(公告)号:US08168627B2
公开(公告)日:2012-05-01
申请号:US12724966
申请日:2010-03-16
申请人: Fernand Labrie , Rock Breton , Shankar Mohan Singh , Rene Maltais
发明人: Fernand Labrie , Rock Breton , Shankar Mohan Singh , Rene Maltais
IPC分类号: A61K31/54 , A61K31/5375 , A61K31/4439 , A61K31/454 , A61K31/435 , A61K31/415 , A61K31/4155 , C07D417/02 , C07D413/02 , C07D221/04 , C07D401/02 , C07D403/02 , C07D233/54 , C07D233/02
CPC分类号: C07D417/12 , C07D207/40 , C07D211/48 , C07D233/74 , C07D233/86
摘要: Compounds having the structure (or their salts): are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. The compounds can be formulated together with pharmaceutically acceptable diluents or carriers or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.
摘要翻译: 具有结构(或其盐))的化合物用于治疗或降低获得雄激素依赖性疾病如前列腺癌,良性前列腺增生,多囊卵巢综合征,痤疮,多毛症,皮脂溢,雄激素性脱发和男性秃发的可能性。 化合物可与药学上可接受的稀释剂或载体一起配制,或以其它方式制成任何药物剂型。 还公开了与其它活性药剂的组合。
-
3.
公开(公告)号:US09682960B2
公开(公告)日:2017-06-20
申请号:US14567970
申请日:2014-12-11
IPC分类号: C07D401/04 , C07D403/12 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/506 , A61K31/517 , A61K45/06 , C07D401/12 , C07D401/14 , A61K38/09 , A61K31/58
CPC分类号: C07D403/12 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/58 , A61K38/09 , A61K45/06 , C07D401/12 , C07D401/14 , A61K2300/00
摘要: Compounds having the structure or their salts: are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia, male baldness, muscle atrophy and weakness, sarcopenia, male hypogonadism, erectile dysfunction, female sexual dysfunction and osteoporosis. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.
-
公开(公告)号:US20100227855A1
公开(公告)日:2010-09-09
申请号:US12724966
申请日:2010-03-16
申请人: Fernand Labrie , Rock Breton , Shankar Mohan Singh , René Maltais
发明人: Fernand Labrie , Rock Breton , Shankar Mohan Singh , René Maltais
IPC分类号: A61K31/541 , C07D233/86 , A61K31/426 , A61P3/10 , A61P19/10 , A61P7/06 , A61P17/14 , A61P9/10 , A61P35/00 , A61P3/04 , C07D403/12 , C07D413/12 , A61K31/5377 , C07D401/12 , A61K31/454 , C07D417/12 , C07D295/155 , A61K31/495
CPC分类号: C07D417/12 , C07D207/40 , C07D211/48 , C07D233/74 , C07D233/86
摘要: Compounds having the structure (or their salts): are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. The compounds can be formulated together with pharmaceutically acceptable diluents or carriers or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.
摘要翻译: 具有结构(或其盐))的化合物用于治疗或降低获得雄激素依赖性疾病如前列腺癌,良性前列腺增生,多囊卵巢综合征,痤疮,多毛症,皮脂溢,雄激素性脱发和男性秃发的可能性。 化合物可与药学上可接受的稀释剂或载体一起配制,或以其它方式制成任何药物剂型。 还公开了与其它活性药剂的组合。
-
公开(公告)号:US07709516B2
公开(公告)日:2010-05-04
申请号:US11452545
申请日:2006-06-14
申请人: Fernand Labrie , Rock Breton , Shankar Mohan Singh , René Maltais
发明人: Fernand Labrie , Rock Breton , Shankar Mohan Singh , René Maltais
IPC分类号: A61K31/45 , A61K31/4166
CPC分类号: C07D417/12 , C07D207/40 , C07D211/48 , C07D233/74 , C07D233/86
摘要: Compounds having the structure (or their salts): are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. The compounds can be formulated together with pharmaceutically acceptable diluents or carriers or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.
摘要翻译: 具有结构(或其盐))的化合物用于治疗或降低获得雄激素依赖性疾病如前列腺癌,良性前列腺增生,多囊卵巢综合征,痤疮,多毛症,皮脂溢,雄激素性脱发和男性秃发的可能性。 化合物可与药学上可接受的稀释剂或载体一起配制,或以其它方式制成任何药物剂型。 还公开了与其它活性药剂的组合。
-
-
-
-